1887

Journal of General Virology header logo

Volume 105, Issue 8

Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms Open Access

Abstract

Rhabdoviral vectors can induce lysis of cancer cells. While studied almost exclusively at 37 °C, viruses are subject to a range of temperatures , including temperatures ≤31 °C. Despite potential implications, the effect of temperatures <37 °C on the performance of rhabdoviral vectors is unknown. We investigated the effect of low anatomical temperatures on two rhabdoviruses, vesicular stomatitis virus (VSV) and Maraba virus (MG1). Using a metabolic resazurin assay, VSV- and MG1-mediated oncolysis was characterized in a panel of cell lines at 28, 31, 34 and 37 °C. The oncolytic ability of both viruses was hindered at 31 and 28 °C. Cold adaptation of both viruses was attempted as a mitigation strategy. Viruses were serially passaged at decreasing temperatures in an attempt to induce mutations. Unfortunately, the cold-adaptation strategies failed to potentiate the oncolytic activity of the viruses at temperatures <37 °C. Interestingly, we discovered that viral replication was unaffected at low temperatures despite the abrogation of oncolytic activity. In contrast, the proliferation of cancer cells was reduced at low temperatures. Equivalent oncolytic effects could be achieved if cells at low temperatures were treated with viruses for longer times. This suggests that rhabdovirus-mediated oncolysis could be compromised at low temperatures where therapeutic windows are limited.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): oncolytic , rhabdovirus , temperature and viral vector
Funding
This study was supported by the:
  • Cancer Research Society (Award 843296)
    • Principle Award Recipient: ByramW. Bridle
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.002010
2024-08-22
2024-09-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/105/8/jgv002010.html?itemId=/content/journal/jgv/10.1099/jgv.0.002010&mimeType=html&fmt=ahah

References

  1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prevent 2016; 25:16–27 [View Article]
     [Google Scholar]
  2. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014; 2:295–300 [View Article] [PubMed]
     [Google Scholar]
  3. Keck T, Leiacker R, Riechelmann H, Rettinger G. Temperature profile in the nasal cavity. Laryngoscope 2000; 110:651–654 [View Article] [PubMed]
     [Google Scholar]
  4. Ceron RJ, Radwin RG, Henderson CJ. Hand skin temperature variations for work in moderately cold environments and the effectiveness of periodic rewarming. Am Ind Hyg Assoc J 1995; 56:558–567 [View Article] [PubMed]
     [Google Scholar]
  5. Nardin RA, Fogerson PM, Nie R, Rutkove SB. Foot temperature in healthy individuals: effects of ambient temperature and age. J Am Podiatr Med Assoc 2010; 100:258–264 [View Article] [PubMed]
     [Google Scholar]
  6. Koga H, Mori K, Ono H, Kuwahara M, Matsuse E. Intraoperative regional thermography during surgery of brain tumors. Neurol Med Chir 1987; 27:1033–1038 [View Article] [PubMed]
     [Google Scholar]
  7. Gorbach AM, Heiss JD, Kopylev L, Oldfield EH. Intraoperative infrared imaging of brain tumors. J Neurosurg 2004; 101:960–969 [View Article] [PubMed]
     [Google Scholar]
  8. Ecker RD, Goerss SJ, Meyer FB, Cohen-Gadol AA, Britton JW et al. Vision of the future: initial experience with intraoperative real-time high-resolution dynamic infrared imaging. Technical note. J Neurosurg 2002; 97:1460–1471 [View Article] [PubMed]
     [Google Scholar]
  9. Shimatani A, Hoshi M, Oebisu N, Iwai T, Takada N et al. Clinical significance of thermal detection of soft-tissue tumors. Int J Clin Oncol 2020; 25:1418–1424 [View Article] [PubMed]
     [Google Scholar]
  10. Szymańska A, Szymański M, Gołąbek W, Drelich-Zbroja A, Jargiełło T. Doppler ultrasound appearance of neck tumors. J Ultrason 2018; 18:96–102 [View Article] [PubMed]
     [Google Scholar]
  11. Kateb B, Yamamoto V, Yu C, Grundfest W, Gruen JP. Infrared thermal imaging: a review of the literature and case report. Neuroimage 2009; 47 Suppl 2:T154–62 [View Article] [PubMed]
     [Google Scholar]
  12. Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther 2014; 22:420–429 [View Article] [PubMed]
     [Google Scholar]
  13. Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009; 17:1814–1821 [View Article] [PubMed]
     [Google Scholar]
  14. Kimpel J, Urbiola C, Koske I, Tober R, Banki Z et al. The oncolytic virus VSV-GP is effective against malignant melanoma. Viruses 2018; 10:108 [View Article] [PubMed]
     [Google Scholar]
  15. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR et al. A recombinant vesicular stomatitis virus ebola vaccine. N Engl J Med 2017; 376:330–341 [View Article] [PubMed]
     [Google Scholar]
  16. ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ 2017; 189:E819–E827 [View Article] [PubMed]
     [Google Scholar]
  17. Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F et al. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother 2018; 7:117–128 [View Article] [PubMed]
     [Google Scholar]
  18. Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 2005; 86:2269–2274 [View Article]
     [Google Scholar]
  19. Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004; 39:920–927 [View Article] [PubMed]
     [Google Scholar]
  20. Brun J, McManus D, Lefebvre C, Hu K, Falls T et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 2010; 18:1440–1449 [View Article] [PubMed]
     [Google Scholar]
  21. Beier KT, Saunders A, Oldenburg IA, Miyamichi K, Akhtar N et al. Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors. Proc Natl Acad Sci U S A 2011; 108:15414–15419 [View Article] [PubMed]
     [Google Scholar]
  22. Whelan SP, Ball LA, Barr JN, Wertz GT. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 1995; 92:8388–8392 [View Article] [PubMed]
     [Google Scholar]
  23. Le Boeuf F, Gebremeskel S, McMullen N, He H, Greenshields AL et al. Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models. Mol Ther Oncolytics 2017; 6:80–89 [View Article] [PubMed]
     [Google Scholar]
  24. Lei C, Yang J, Hu J, Sun X. On the calculation of TCID50 for quantitation of virus infectivity. Virol Sin 2021; 36:141–144 [View Article]
     [Google Scholar]
  25. Kiesslich S, Kamen AA. Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnol Adv 2020; 44:107608 [View Article] [PubMed]
     [Google Scholar]
  26. Brien JD, Lazear HM, Diamond MS. Propagation, quantification, detection, and storage of West Nile virus. Curr Protoc Microbiol 2013; 31:15D [View Article] [PubMed]
     [Google Scholar]
  27. Quah BJC, Parish CR. The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J Vis Exp 2010; 2010:2259 [View Article] [PubMed]
     [Google Scholar]
  28. Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S et al. Privileged antigen presentation in splenic B cell follicles maximizes T cell responses in prime-boost vaccination. J Immunol 2016; 196:4587–4595 [View Article] [PubMed]
     [Google Scholar]
  29. Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev 2020; 17:349–358 [View Article] [PubMed]
     [Google Scholar]
  30. Altomonte J, Wu L, Meseck M, Chen L, Ebert O et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 2009; 16:266–278 [View Article] [PubMed]
     [Google Scholar]
  31. Altomonte J, Wu L, Chen L, Meseck M, Ebert O et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008; 16:146–153 [View Article] [PubMed]
     [Google Scholar]
  32. Melzer MK, Lopez-Martinez A, Altomonte J. Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”. Biomedicines 2017; 5:8 [View Article] [PubMed]
     [Google Scholar]
  33. Ziegler CM, Botten JW. Defective interfering particles of negative-strand RNA viruses. Trends Microbiol 2020; 28:554–565 [View Article] [PubMed]
     [Google Scholar]
  34. Frensing T. Defective interfering viruses and their impact on vaccines and viral vectors. Biotechnol J 2015; 10:681–689 [View Article] [PubMed]
     [Google Scholar]
  35. Danciu C, Falamas A, Dehelean C, Soica C, Radeke H et al. A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior. Cancer Cell Int 2013; 13:75 [View Article] [PubMed]
     [Google Scholar]
  36. Ammerman NC, Beier-Sexton M, Azad AF. Growth and maintenance of vero cell lines. Curr Protoc Microbiol 2008; 4:4E [View Article] [PubMed]
     [Google Scholar]
  37. Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD et al. Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch cultues. Cytotechnology 1997; 23:47–54 [View Article] [PubMed]
     [Google Scholar]
  38. Zhu L, Li X, Xu H, Fu L, Gao GF et al. Multiple RNA virus matrix proteins interact with SLD5 to manipulate host cell cycle. J Gen Virol 2021; 102:001697 [View Article] [PubMed]
     [Google Scholar]
  39. Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol 2018; 39:209–221 [View Article] [PubMed]
     [Google Scholar]
  40. Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther 2018; 26:1008–1019 [View Article] [PubMed]
     [Google Scholar]
  41. Harrington K, Freeman DJ, Kelly B, Harper J, Soria J-C. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 2019; 18:689–706 [View Article] [PubMed]
     [Google Scholar]
  42. O’Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10:1349–1358 [View Article] [PubMed]
     [Google Scholar]
  43. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8:341–348 [View Article] [PubMed]
     [Google Scholar]
  44. Garofalo M, Saari H, Somersalo P, Crescenti D, Kuryk L et al. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release 2018; 283:223–234 [View Article] [PubMed]
     [Google Scholar]
  45. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17:1667–1676 [View Article] [PubMed]
     [Google Scholar]
  46. Vos LMC, Aronson SL, van Driel WJ, Huitema ADR, Schagen van Leeuwen JH et al. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2022; 78:86–102 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.002010
Loading
Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms
J. Gen. Virol. 105, 002010 (2024); https://doi.org/10.1099/jgv.0.002010
/content/journal/jgv/10.1099/jgv.0.002010
/content/journal/jgv/10.1099/jgv.0.002010
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error